Last updated: February 22, 2026
What is NDC 70069-0091?
NDC 70069-0091 represents Relebar (carbinoxamine maleate and pseudoephedrine HCl), marketed primarily for allergic rhinitis and cold symptoms. It is a combination antihistamine and decongestant. The drug is primarily used in the United States, with approval and entry into markets varying based on formulation and regulatory status.
Market Size and Demand
Current Market Entrants
- Relebar addresses a niche: allergic and cold symptom treatment.
- Historically, antihistamines combined with decongestants maintain steady demand, driven by seasonal illnesses and allergy outbreaks.
- In 2022, the U.S. OTC cold/flu products market was valued at approximately $1.4 billion. The antihistamine segment comprises roughly 15% of the total OTC cold/flu market [1].
Prescriptions and Sales Data
- Prescription volume for combination antihistamines has hovered around 2.5 million units annually.
- OTC sales account for approximately 70% of total sales, signaling strong consumer preference outside physicians' prescriptions.
- Relebar competes against branded and generic products such as Claritin-D, Sudafed, and their equivalents.
Competitive Landscape
- OTC antihistamine/ decongestant products are saturated, with generics dominating shelf space.
- Key competitors include pseudoephedrine-based products like Sudafed, as well as antihistamines such as loratadine and cetirizine.
Regulatory and Supply Considerations
- Pseudoephedrine products face strict sales tracking and restrictions under the Combat Methamphetamine Epidemic Act (CMEA).
- Manufacturing constraints, including raw material sourcing, influence supply stability.
Price Trends and Projections
Current Pricing Landscape
| Product |
Current Retail Price (Estimated) |
Strength & Formulation |
Brand Status |
| Relebar (70069-0091) |
$12–$15 (30-count tablets) |
4 mg/60 mg per tablet |
Generic |
| Branded alternatives |
$16–$20 |
Similar formulation |
Brand |
| OTC competitors |
$8–$12 |
Varies |
Generic |
- Relebar's per-unit price remains comparable with generic combination antihistamines, reflecting minimal premium due to generic competition.
Future Price Trajectories
- Market saturation and increased competition likely will keep prices stable or slightly decrease.
- Regulatory constraints on pseudoephedrine sales may limit supply, potentially exerting upward price pressure in certain regions.
- Inflation and raw material costs could challenge margins, but pricing power remains limited due to intense competition.
- Introduction of new formulations or combination products could either fragment the market further or create premium offerings, influencing prices.
Price Projections (Next 3-5 Years)
| Year |
Price Range (Per 30-count pack) |
Market Factors |
| 2023 |
$12–$15 |
Stable demand, intense generic competition |
| 2024 |
$11–$14 |
Supply chain pressures, regulatory influences |
| 2025 |
$11–$14 |
Market saturation, minor price reductions anticipated |
Key Market Dynamics
- Consumer shifts toward OTC products for ease of access may sustain demand.
- Generics penetration remains high; new entrants will exert price compression.
- Regulation tightening on pseudoephedrine sales could diminish supply, potentially creating regional price variance.
- The COVID-19 pandemic led to an increase in cold/flu product consumption, a trend that normalized but may recur seasonally.
Summary Insights
- NDC 70069-0091 operates in a highly competitive, mature market.
- Prices are constrained by an oversaturated OTC segment, with minimal margins for premiumization.
- Supply disruptions due to pseudoephedrine regulations may cause regional shortages, impacting prices.
- The product's future remains tied to seasonal demand, regulatory environment, and competitive dynamics.
Key Takeaways
- Relebar’s market share is limited by competition from existing OTC combination products.
- Pricing is expected to decline slightly or stabilize over the next five years, barring supply shocks.
- The pseudoephedrine regulatory landscape compresses availability and influences regional pricing.
- Market growth is linked to seasonal illness prevalence rather than innovation or new formulations.
- Entry barriers are low for new generics, further pressuring prices.
FAQs
Q1: What factors influence the price of NDC 70069-0091?
Supply and demand dynamics, regulatory restrictions on pseudoephedrine, competitive intensity from generics, and raw material costs.
Q2: How does regulation impact the marketability of pseudoephedrine-based products?
Strict sales tracking, record-keeping requirements, and purchase limits limit distribution, impacting overall supply and potential price fluctuations.
Q3: What is the potential for new competitors entering the market?
High, given the standardized nature of the formulation; new entrants can quickly capture market share, adding downward pressure on prices.
Q4: Are there regional pricing differences expected?
Yes. Regulatory restrictions on pseudoephedrine sales vary by state, causing regional price variability.
Q5: How might consumer preferences shift in this market?
Consumers may prefer single-ingredient or alternative OTC medications, reducing demand for combination products like Relebar.
References
[1] Statista. (2022). U.S. OTC cold and flu remedies market size. https://www.statista.com
